Chemours stock performance snapshot after recent moves
Chemours (CC) has seen mixed share performance recently, with a 7% gain over the past week, a 14.4% decline over the past month, and a 49.2% rise across the past 3 months.
See our latest analysis for Chemours.
At a share price of US$17.57, Chemours has seen strong short term momentum with a 90 day share price return of 49.2%, but its 5 year total shareholder return of 21.4% loss highlights a much tougher long term picture. Recent moves suggest investors are reassessing Chemours after earlier weakness, with the sharp 3 month rebound hinting at changing expectations for growth or risk, even as longer term total shareholder returns remain negative.
If Chemours has you thinking about materials and industrial supply chains, this could be a good moment to check out 8 top copper producer stocks as another potential source of ideas.
With Chemours trading at US$17.57, sitting below the average analyst price target and showing a large modelled intrinsic discount despite recent gains, is there still a potential entry point here or is this already reflected in the current share price?
Most Popular Narrative: 7.6% Overvalued
The most followed narrative puts Chemours' fair value around $16.33, slightly below the last close of $17.57, which frames the current share price as a modest premium.
Secular demand growth for advanced materials tied to electrification, renewables, data centers, and energy storage is generating incremental sales in higher-value applications for APM; ongoing portfolio optimization and pricing improvements in these segments are structurally enhancing net margins and improving earnings quality.
Want to see how this story translates into numbers? Revenue shifts, margin rebuild, and a future earnings profile all sit at the core of this fair value call. The key is how much profit power the narrative expects Chemours to build over the next few years, and what kind of earnings multiple that would support.
Result: Fair Value of $16.33 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still clear pressure points, with unresolved PFAS litigation and ongoing regulatory scrutiny that could affect cash flows and challenge the current overvaluation thesis.
Find out about the key risks to this Chemours narrative.
Another angle on Chemours' value
While the most popular narrative frames Chemours as about 7.6% overvalued versus a fair value of US$16.33, our DCF model points the other way. On that view, the shares at US$17.57 sit around 64.9% below an estimated future cash flow value of US$49.99. When two methods disagree this much, investors may want to consider which approach they find more reliable.
Look into how the SWS DCF model arrives at its fair value.
Next Steps
With such a split view around Chemours, it makes sense to look at the numbers yourself and decide where you stand. If you want to quickly see how the positives and negatives line up, take a look at the 3 key rewards and 2 important warning signs to weigh both sides before you move on.
Looking for more investment ideas?
If Chemours has sharpened your thinking, do not stop here. Broaden your watchlist with ideas that line up with your goals and risk comfort.
- Target stronger value potential by scanning companies our tools highlight as 48 high quality undervalued stocks on both quality and pricing signals.
- Build a steadier income stream by focusing on businesses in our list of 14 dividend fortresses that emphasise higher yields with resilience.
- Protect the downside first by filtering for companies in our 68 resilient stocks with low risk scores that show more robust risk profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com